Accordingly, the CRISPR/Cas9 nanosystem developed in this research can efficiently enrich the tumor region under probiotic drive and can precisely and controllably knock down IDO1 under US irradiation, avoiding the lack of targeting and drug resistance of traditional inhibitors. Here, IDO1 is linked to neoplasm.